---
title: "SpyGlass Pharma, Inc. (SGP.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SGP.US/overview.md"
symbol: "SGP.US"
name: "SpyGlass Pharma, Inc."
parent: "https://longbridge.com/en/quote/SGP.US.md"
datetime: "2026-04-15T03:00:36.027Z"
locales:
  - [en](https://longbridge.com/en/quote/SGP.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SGP.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SGP.US/overview.md)
---

# SpyGlass Pharma, Inc. (SGP.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Address | 27061 Aliso Creek Road, Suite 100, Aliso Viejo, California, United States |
| Website | [www.spyglasspharma.com](https://www.spyglasspharma.com) |

## Company Profile

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost.

## Key Executives

| Name | Title |
|------|-------|
| Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman |
| Patrick H. Mooney | CEO & Director |
| Chetan Pujara | Chief Research & Development Officer |
| Glenn Sussman | Co-founder & Chief Technology Advisor |
| Jean-Frederic Viret | Chief Financial Officer |
| Zachary Scheiner | Independent Director |
| Bilal Arshad Khan | Independent Director |
| Elizabeth G. O’Farrell | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| RA Capital Management, L.P. | 24.00% | 2026-02-09 |
| New Enterprise Associates, Inc. | 22.12% | 2026-02-13 |
| Vensana Capital Management, LLC | 9.90% | 2026-02-09 |
| Sands Capital Ventures, LLC | 7.48% | 2026-02-06 |
| Gilde Healthcare Partners B.V. | 6.54% | 2026-02-09 |
| Samsara BioCapital LLC | 6.31% | 2026-02-09 |
| Malik Y. Kahook | 2.61% | 2026-02-06 |
| Franklin Resources, Inc. | 0.90% | 2026-02-28 |
| Bilal Khan | 0.83% | 2026-02-09 |
| Patrick Mooney | 0.55% | 2026-02-06 |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**